AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

A new study finds no significant differences in cardiovascular and thromboembolic risks among biologics for psoriasis or ...